SCHEMBL8060089

SCHEMBL8060089

CCCC(C(=O)O)c1[nH]c2ccccc2c1P(=O)(O)Cc1ccccc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.34
ALDH1A1 P00352 2/20 0.34
HSD17B10 Q99714 1/20 0.34
MEN1 O00255 4/20 0.34
KMT2A Q03164 4/20 0.34
EGFR P00533 1/20 0.34
SRC P12931 1/20 0.34
MAPT P10636 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
NPC1 O15118 1/20 0.34
PKM P14618 1/20 0.34
RAB9A P51151 1/20 0.34
ESR1 P03372 1/20 0.34
ESR2 Q92731 1/20 0.34
DRD2 P14416 1/20 0.33
MET P08581 1/20 0.33
RXFP1 Q9HBX9 1/20 0.33
MMP1 P03956 1/20 0.33
FFAR1 O14842 1/20 0.33
GPR84 Q9NQS5 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7610576 0.91 MEN1 (0.37) KDM4EALDH1A1MEN1KMT2AEGFR
SCHEMBL7607365 0.83 KDM4E (0.37) KDM4EALDH1A1MEN1KMT2AEGFR
SCHEMBL7604578 0.76 MEN1 (0.36) KDM4EALDH1A1HSD17B10MEN1KMT2A
SCHEMBL7604710 0.75 ALOX5 (0.38) KDM4EALDH1A1MEN1KMT2AEGFR
SCHEMBL7609378 0.71 ACP3 (0.39) KDM4EALDH1A1HSD17B10
SCHEMBL7610445 0.69 PPARG (0.41) ALDH1A1MMP1
SCHEMBL1121944 0.69 OXER1 (0.42) KDM4EALDH1A1HSD17B10
SCHEMBL7611820 0.68 MMP1 (0.35) KDM4EALDH1A1HSD17B10MMP1
SCHEMBL7604621 0.68 MEN1 (0.39) KDM4EALDH1A1HSD17B10MEN1KMT2A
SCHEMBL7604500 0.67 ALOX5 (0.39) KDM4EALDH1A1MEN1KMT2AEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1005348-A1 NAALADASE COMPOSITIONS AND METHODS FOR TREATING GLUTAMATE ABNORMALITY AND EFFECTING NEURONAL ACTIVITY IN ANIMALS GUILFORD PHARMACEUTICALS INC. (US) 2000-06-07 EP disclosed
WO-1998013046-A1 NAALADASE COMPOSITIONS AND METHODS FOR TREATING GLUTAMATE ABNORMALITY AND EFFECTING NEURONAL ACTIVITY IN ANIMALS GUILFORD PHARMACEUTICALS INC. (US) 1998-04-02 WO disclosed